The clinical, cardiovascular and neuroendocrine profile of ampreloxetine showed target engagement of residual peripheral autonomic neurons and a sustained standing blood pressure effect, which is ...

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with atherosclerotic cardiovascular ...

Data from an open-label trial showed that foralumab treatment eased fatigue and lessened disability for some people with ...

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

Health and Human Services Secretary Robert F. Kennedy Jr. has misleadingly claimed that vaccines are not tested in ...

Fremanezumab (Ajovy) reduced depression symptoms and monthly migraine attacks in people with episodic or chronic migraine and ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in ...

As such, the notion of a non-pharmacological, side-effect-free intervention — like an open-label placebo — is particularly attractive. The study also prompts a broader conversation about how ...